GlassScriptPhysician profile
Robert Hamilton III
NPI 1295115178
$2,369.02
in general payments reported to CMS, 2019-2025
19 companies · $667 in 2025
The $667 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.83 · 2020: $75.61 · 2021: $287 · 2022: $508 · 2023: $461 · 2024: $360 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,079 · Travel and Lodging: $376 · Education: $33.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.54 |
| Travel and Lodging | $375.82 |
| Education | $33.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $669.00 | 2022-2025 | Vns Therapy |
| Abbvie INC. | $460.21 | 2022-2024 | |
| Pfizer INC. | $351.17 | 2023-2024 | |
| Ucb, INC. | $248.11 | 2020-2025 | Fintepla, Nayzilam, Briviact |
| Biohaven Pharmaceuticals, INC. | $130.59 | 2021 | |
| Allergan, INC. | $81.38 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $69.29 | 2022 | |
| Jazz Pharmaceuticals INC. | $55.53 | 2022 | |
| Eisai INC. | $51.78 | 2022 | |
| Neuropace, INC. | $42.42 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $35.52 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $33.44 | 2024 | |
| Lilly USA, LLC | $31.19 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $30.73 | 2021 | |
| Avion Pharmaceuticals | $22.59 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $17.03 | 2022 | |
| Biogen, INC. | $15.43 | 2021 | |
| Sk Life Science, INC. | $12.78 | 2022 | |
| Avanir Pharmaceuticals, INC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hamilton III listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.